BOSTON--(BUSINESS WIRE)--IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of cancer and inflammatory disease, today announced the appointment of seven leading physicians to its clinical advisory board (CAB). The CAB members, many of whom have played an integral role in the development of currently approved immunotherapies, will provide strategic medical and clinical guidance for IFM’s research and development programs.
“We are delighted to welcome this accomplished and distinguished group of immunotherapy pioneers to IFM’s clinical advisory board,” said Gary D. Glick, Ph.D., co-founder and CEO of IFM Therapeutics. “At IFM, we are committed to leveraging our expertise in the fundamental biology of innate immunity and our translational medicine capabilities to advance novel treatments for cancer and inflammatory disorders. The experience and guidance of our newly formed CAB will be instrumental as we transition our research programs into clinical development and expand our pipeline of novel immunomodulators.”
Members of the IFM clinical advisory board include:
- Hal Hoffman, M.D. – Professor of Pediatrics and Medicine and Chief of the Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego
- Howard Kaufman, M.D., F.A.C.S. – Professor of Surgery and Medicine, Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey
- Jeffrey Miller, M.D. – Professor of Medicine, University of Minnesota Medical School and Deputy Director, Masonic Cancer Center, University of Minnesota
- Saurabh Saha, M.D., Ph.D. – Venture Partner, Atlas Venture; Past President and CEO, Delinia; Chief Medical Officer, Synlogic; President, BioMed Valley Discoveries
- Neil H. Segal, M.D., Ph.D. – Medical Oncologist, Clinical Director, Immunotherapeutics Group, Memorial Sloan Kettering Cancer Center
- Jedd Wolchok, M.D., Ph.D. – Chief, Melanoma & Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center (MSK); Associate Director, Ludwig Center for Cancer Immunotherapy at MSK; Director, Parker Institute for Cancer Immunotherapy at MSK
In 2016, the company closed a $27 million Series A round of financing led by Atlas Venture and Abingworth, with participation from Novartis, and assembled a leading scientific advisory board with experts in immunology, medicinal chemistry and drug discovery.
About the Innate Immune System
Innate immunity is our body’s first response and first line of defense to external threats, such as viruses. If the immune system consistently under-responds or over-responds, serious diseases can result. IFM Therapeutics has developed first-in-class agents to control pattern recognition receptors, which are powerful mediators of innate immune responses. By precisely activating these mediators, IFM’s drug candidates aim to enhance immune responses for the treatment of cancer. Conversely, silencing these responses has the potential to treat a range of inflammatory and autoimmune disorders.
About IFM Therapeutics
IFM Therapeutics is a privately held biopharmaceutical company based in Boston, Massachusetts. The company was founded in 2015 by an international group of preeminent scientists and physicians who have spent decades understanding innate immunity and the role it plays in regulating the immune system. IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. Candidates in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. For more information, please visit www.ifmthera.com.